| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Omigapil is a dibenzoxazine heptadecane drug. Omigapil has been used in clinical trials investigating its use for the treatment of congenital muscular dystrophy.
|
| Molecular Formula |
C19H17NO
|
|---|---|
| Molecular Weight |
275.34
|
| Exact Mass |
275.131
|
| CAS # |
181296-84-4
|
| Related CAS # |
Omigapil maleate
|
| PubChem CID |
6419718
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31
|
| InChi Key |
QLMMOGWZCFQAPU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3
|
| Chemical Name |
N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine
|
| Synonyms |
CGP3466B free base; TCH346
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Omigapil (CGP3466B) is dissolved in phosphate-buffered saline (PBS, 0.1 mol/L, pH 7.4)[1]. (Please use freshly prepared in vivo formulations for optimal results.)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6319 mL | 18.1594 mL | 36.3187 mL | |
| 5 mM | 0.7264 mL | 3.6319 mL | 7.2637 mL | |
| 10 mM | 0.3632 mL | 1.8159 mL | 3.6319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT01805024
Conditions:Congenital Muscular DystrophyLink: https://clinicaltrials.gov/ct2/show/NCT00036413
Conditions:Amyotrophic Lateral SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT00072709
Conditions:Amyotrophic Lateral Sclerosis
Title:A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
Status:Completed
updateDate:2011-11-23
Ctid:NCT00407212
Link: https://clinicaltrials.gov/ct2/show/NCT00407212
Conditions:Parkinson's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT00230074
Conditions:Amyotrophic Lateral SclerosisProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
